You Searched For: Lactacystin

Supplier: Enzo Life Sciences

Description: Key inhibitor for use in proteasome research.

Catalog Number: (89161-586)

Supplier: Enzo Life Sciences

Description: Highly specific, cell permeable, and irreversible 20S proteasome inhibitor. Inhibits ubiquitin proteasome pathway in cell culture (IC50=1µM). It has been suggested that the natural product lactacystin acts as a precursor for clasto-lactacystin β-lactone and that the latter is the sole species that interacts with the proteasome. Inhibits cathepsin A. Leads to a reduction of adipogenesis. Induces neurite growth and inhibits cell cycle progression. 

Catalog Number: (80052-808)

Supplier: MilliporeSigma

Description: A highly specific, cell-permeable, and irreversible proteasome inhibitor

Certificates

Catalog Number: (80052-806)

Supplier: MilliporeSigma

Description: An irreversible proteasome inhibitor and Streptomyces metabolite that acts as a highly specific inhibitor of the 20S proteasome (MCP; multicatalytic proteinase complex)

SDS Certificates

Catalog Number: (77694-646)

Supplier: LGC Standards

Description: (+)-Lactacystin, TRC, LGC Standards

New Product

Supplier: Adipogen

Description: Induces neuritogenesis. Potent and selective irreversible proteasome inhibitor. Specifically inhibits 20S proteasome (MCP; multicatalytic complex). Blocks proteasome activity by targeting the catalytic beta-subunit. Apoptosis inducer. Anticancer compound. Upregulates HSP70 and HSP22. Induces differentiation and inhibits cell cycle progression in several tumor cell lines. Inhibits NF-kappaB activation by inhibiting IkappaB degradation. Cathepsin A inhibitor. beta-Secretase activity inhibitor. Anti-adipogenic. Autophagy inducer.

Catalog Number: (80053-882)

Supplier: MilliporeSigma

Description: Set contains 1mg of Proteasome Inhibitor I (80053-874, -876), 200µg of Lactacystin (80052-806), and 1mg of MG-132 (80053-194, -196)

Catalog Number: (102988-280)

Supplier: Adipogen

Description: Potent and selective irreversible and cell permeable proteasome inhibitor. Inhibits the chymotrypsin-like, trypsin-like and caspase-like peptidase activity of the proteasome. The active metabolite of lactacystin with higher potency since it does not require hydrolysis in order to become cell permeable. Calpain and cathepsin inhibitor. Apoptosis inducer. Anticancer compound. Induces differentiation and inhibits cell cycle progression in several tumor cell lines. Induces neuritogenesis. Autophagy inducer.

Catalog Number: (102988-286)

Supplier: Adipogen

Description: Potent, irreversible inhibitor of all the 3 proteolytic activities of the mammalian 20S proteasome. beta5 subunit: chymotrypsin-like (EC50 = 3.5nM) beta2 subunit: trypsin-like (EC50 = 28nM) beta1 subunit: caspase-like or peptidyl-glutamyl peptide-hydrolyzing (PGPH) (EC50 = 430nM) Potent anticancer compound. Triggers apoptosis, with distinct proteasome activity and mechanism of action compared to bortezomib (Velcade) . Most potent suppressor of NF-kappaB activation, compared with bortezomib, MG-132 , N-acetyl-leucyl-leucyl-norleucinal (ALLN) and lactacystin . Inhibitor of TNF-alpha, IL-1, IL-6, ICAM-1 and VEGF synthesis. Displays a longer inhibition duration than bortezomib. Potent antileukemic activity against bortezomib-resistant leukemia cells.

Catalog Number: (89162-330)

Supplier: Enzo Life Sciences

Description: Studies have demonstrated that PR39, a proline/arginine rich 39 amino acid antibacterial peptide originally derived from porcine bone marrow, exhibits a broad spectrum of biological activities, including the ability to induce angiogenesis and to limit inflammatory damage in a variety of animal models. The angiogenic effect is in part explained by the ability of PR39 to inhibit proteasome-dependent degradation of the transcription factor HIF-1a, while anti-inflammatory activity is associated with inhibition of IκBα degradation that in turn prevents activation of NFκB-dependent gene expression. The activities of PR39 reside in the N-terminal portion of the molecule encompassed by PR11. The most recent findings have demonstrated that PR39 is a non-competitive and reversible inhibitor of the proteasome function, which is achieved by a unique allosteric mechanism allowing for specific inhibition of degradation of selected proteins without affecting total proteasome-dependent proteolysis. A proline-arginine-rich 11 amino acid peptide derived from the naturally occurring peptide antibiotic PR39. PR39 has been shown to act as an inhibitor of both 20S and 26S proteasomes with proposed selectivity for the inhibition of the degradation of IκBα, HIF-1a and certain other proteins. PR39 has been reported to inhibit the proteasomal degradation of IκBα without effecting overall proteasome activity, or degradation of p21Cip1/Waf1 and c-fos, cell-cycle genes regulated by proteasome-dependent degradation. In vitro studies have demonstrated PR39 to be an efficient inhibitor of all three activities of the 20S proteasome. Unlike MG132 and lactacystin, long-term exposure to PR39 shows little toxicity or induction of HSP-70. In mouse models of myocardial infarction it has been shown that infusion with PR11 results in a significant reduction of myocardial infarct size. PR39, PR11 and related peptides may therefore provide novel means to regulate cellular function and the control of NF-κB-dependent gene expression for therapeutic purposes.

Catalog Number: (102870-662)

Supplier: R&D Systems

Description: LACTACYSTIN (200 UG)

Catalog Number: (ABCA_AB141411-200U)

Supplier: ABCAM INC.

Description: LACTACYSTIN, PROTEASOME AB141411-200UG

New Product

Catalog Number: (ABCA_AB141412-100U)

Supplier: ABCAM INC.

Description: CLASTO-LACTACYSTIN BETA- AB141412-100UG

New Product

Catalog Number: (89161-634)

Supplier: Enzo Life Sciences

Description: Key inhibitor for use in proteasome research.